Business Context and Reporting Period
This Form 8-K filing by BioRestorative Therapies, Inc. (Delaware) covers events occurring between June 13, 2019, and July 17, 2019, with the report dated July 11, 2019. The filing details unregistered sales of equity securities and debt restructuring activities.
Key Financial Metrics and Transactions
- Debt Repayment: Repaid $1,089,555 in outstanding convertible notes (including accrued interest and prepayment premiums) between June 13 and July 16, 2019.
- New Debt Issuance: Issued convertible promissory notes with a principal of $430,000 for cash proceeds of $420,000 between June 20 and July 2, 2019.
- Debt-to-Equity Conversion: Issued 585,198 shares of common stock to settle $102,142 of indebtedness (including interest) between July 2 and July 17, 2019.
- Interest Rates: New notes bear interest at 12% per annum.
- Liquidity Impact: Net cash inflow from new note issuance was $420,000, partially offset by significant debt repayments.
Material Changes and Terms
The company executed a significant refinancing strategy involving the repayment of prior obligations and the issuance of new convertible instruments with specific conversion mechanics:
- Conversion Terms (New Notes):
- $260,000 principal convertible after 180 days at 58% of the fair value of common stock.
- $170,000 principal convertible at $0.50 per share, accompanied by a five-year warrant for an equal number of shares at an exercise price of $0.75 per share.
- Mandatory Conversion: The $170,000 tranche is mandatorily convertible upon a public offering at the lower of 75% of the public offering price or $0.50 per share.
- Additional Warrants: A separate five-year warrant to purchase 30,000 shares at $0.56 per share was issued to one lender.
Guidance, Risks, and Unusual Items
The filing does not provide forward-looking guidance, revenue outlook, or management commentary on future operations. The primary focus is on the execution of private placements under Section 4(a)(2) and Section 3(a)(9) of the Securities Act of 1933. The company asserts that no general solicitation was used and that investors were accredited. The dilution from the issuance of 585,198 shares and the potential future dilution from the new convertible notes and warrants represent material risks to existing shareholders.
Investor Verification Checklist
- Verify the total outstanding debt balance following the $1.09M repayment and $430k new issuance.
- Confirm the current fair value of common stock to assess the dilution impact of the 58% conversion discount on the $260,000 note tranche.
- Review the company's cash runway given the net cash position after these transactions.
- Check for any pending public offering that would trigger the mandatory conversion of the $170,000 note tranche.
- Validate the number of shares outstanding post-issuance of the 585,198 shares for debt settlement.